Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì
  #76  
Ñòàðûé 14.03.2003, 15:51
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
Ïðèâîæó î÷åðåäíóþ ñòàòüþ ïî ïðèìåíåíèþ ÎÒ, â ïåðâóþ î÷åðåäü, äëÿ îïïîíåíòîâ ñ èõ ãðîìîãëàñíûìè: øàðëàòàíñêàÿ ìåòîäèêà (åñòåñòâåííî, åñëè àâòîðó îíà íåçíàêîìà, òî äðóãîé îíà è áûòü íå ìîæåò), õîòü îäíà óíèâåðñèòåòñêàÿ êëèíèêà, ðàíäîìèçèïîâàííûå èñïûòàíèÿ è ò. ï. Èíòåðåñíî, õîòü êòî-íèáóäü èç îïïîíåíòîâ, îòðåàãèðóþò íà ýòîò ðàç?
Ïðîøó îáðàòèòü âíèìàíèå èñïûòàíèå áûëî ìíîãîöåíòðîâîå (23 ñïåöèàëèçèðîâàííûõ öåíòðà) è ñêîîðäèíèðîâàíû Èíñòèòóòîì Ôàðìàêîëîãèè óíèâåðñèòåòà Ïàâèÿ (Èòàëèÿ)
È âûâîäû: çíà÷èòåëüíî (!) áîëüøàÿ ýôôåêòèâíîñòü ÎÒ ïî ñðàâíåíèþ ñ øèðîêî ïðèìåíÿåìûì â êëèíè÷åñêîé ïðàêòèêå ãåëåì Essaven.

Íåáîëüøàÿ ñïðàâêà.
Ýññàâåí ãåëü (Essaven)
Ñîñòàâ è ôîðìà âûïóñêà. 100 ã ãåëÿ ñîäåðæàò: 1 ã ýñöèíà, 10000 ÌÅ ãåïàðèíà â âèäå íàòðèåâîé ñîëè, 1 ã ýññåíöèàëüíûõ ôîñôîëèïèäîâ. Ãåëü ïî 40 èëè 100 ã â òóáå.
Ôàðìàêîëîãè÷åñêîå äåéñòâèå. Ýññàâåí ãåëü - ýôôåêòèâíîå âåíîòåðàïåâòè÷åñêîå ñðåäñòâî. Ýñöèí óêðåïëÿåò êàïèëëÿðû, îáëàäàåò àíòèýêññóäàòèâíûì äåéñòâèåì, òîíèçèðóåò âåíû. Ãåïàðèí îêàçûâàåò ïðîòèâîâîñïàëèòåëüíîå äåéñòâèå, ñïîñîáñòâóåò ýíäîãåííîìó ôèáðèíîëèçó, ñòèìóëèðóåò ìèêðîöèðêóëÿöèþ. Ýññåíöèàëüíûå ôîñôîëèïèäû óëó÷øàþò ðåîëîãè÷åñêèå ñâîéñòâà êðîâè è ñòèìóëèðóþò ìèêðîöèðêóëÿöèþ. Ýññàâåí ãåëü îêàçûâàåò îõëàæäàþùåå äåéñòâèå è îáëàäàåò îáåçáîëèâàþùèì ýôôåêòîì.

Ïðîèçâîäèòåëü. RHONE-POULENC RORER, ÑØÀ-Ôðàíöèÿ.


SUBCUTANEOUS OXYGEN-OZONE THERAPY IN INDURATIVE HYPODERMALITIS AND IN LOCALISED LIPODYSTROPHIES: A CLINICAL STUDY OF EFFICACY AND TOLERABILITY.

AU Franzini M., Bignamini A., Micheletti P., Valdenassi L., Agostini G., Richelmi P., Berte F..
SO ACTA TOXICOL. THER.
YR 1993
PG 273-288
AB A multicentric, prospective, randomized, open study was carried out on confirmed by clinical examination to determine the efficacy and tolerability of oxygen-ozone therapy as compared with a topical preparation (Essaven gel). The experiments were carried out in 23 specialist centres and coordinated by the Institute of Pharmacology II, University of Pavia.
The protocol included one or two weekly subcutaneous applications of medical oxygen-ozone containing 1.2-5 microg/ml of ozone for 5 consecutive weeks in quantities of about 5-10 cc per site with a maximum of 250 cc per application. Efficacy, determined by assessing the circumference of the affected area (proportion of the variations equal to or morc than 8%), skin temperature and the overall clinical picture gave significantly better results for oxygen-ozone therapy than the topical control.
Almost all the patients trcated with ozone presented local reactions of little significance which did not interfere with the therapy. No adverse events of a systemic nature were noted, not were there any clinically or statistically significant changes in peripheral haemodynamics, haematology and clinical chemistry. the study shows the significantly greater efficiency of oxygen-ozone therapy in the treatment of lipodystrophies and indurative hypodermatites as compared with Essaven gel, a widely used preparation clinical practice.

AN EMBASE 1994189760
  #77  
Ñòàðûé 14.03.2003, 18:56
Àâàòàð äëÿ Gilarov
Gilarov Gilarov âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 26.07.2001
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 7,196
Ïîáëàãîäàðèëè 713 ðàç(à) çà 691 ñîîáùåíèé
Gilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Î÷àðîâàòåëüíî, Âëàäèìèð ßêîâëåâè÷!
ß òåïåðü áóäó áîðîòüñÿ çà òî, ÷òîáû âìåñòî Ýññàâåíà èñïîëüçîâàëè îçîí. Íî òîëüêî äëÿ ëå÷åíèÿ ëèïîäèñòðîôèè. Ñ÷èòàéòå, ÷òî Âû ìåíÿ óáåäèëè: îçîí çíà÷èòåëüíî ëó÷øå ýññàâåíà (õîòÿ, ÿ íèêîãäà íå óòâåðæäàë îáðàòíîãî). Êîãäà ïîÿâÿòñÿ ïîäîáíûå èññëåäîâàíèÿ äëÿ äðóãèõ îáëàñòåé ïðèìåíåíèÿ îçîíà, íå ñî÷òèòå çà òðóä, äàéòå çíàòü. Èíòåðåñíî, à ñêîëüêî ÷åëîâåê ó÷àñòâîâàëî â èññëåäîâàíèè?
  #78  
Ñòàðûé 14.03.2003, 22:49
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Talking Ïîñìåÿëñÿ îò äóøè

Âëàäèìèð ßêîâëåâè÷!
Âû íå ïåðåñòàåòå óäèâëÿòü è áåç âàñ íà Ðóñìåäñåðâåðå áûëî áû ïðîñòî ñêó÷íî. Ìîæåò áûòü ïîýòîìó ÿ íå ìîãó íèêàê ñäåðæàòüñÿ. ÷òîáû âíîâü íå "ïðîéòèñü" ïî Âàøèì ïîñòèíãàì. Âû ìíå òóïîìó ïîæàëóéñòà ïðèâåäèòå äëÿ íà÷àëà èñòî÷íèêè, ïîäòâåðæäàþùèå, ÷òî ýòîò ñàìûé Ýññàâåí ãåëü - ýôôåêòèâíîå âåíîòåðàïåâòè÷åñêîå ñðåäñòâî. À òî òàêîå âïå÷àòëåíèå, ÷òî îäèí nothing ñðàâíèëè ñ äðóãèì òàêèì æå è âòîðîé îêàçàëñÿ ëó÷øå ïåðâîãî. Òóò ïðàâäà óäèâëÿòüñÿ íå÷åìó õàðèçìû âåäü ó ÎÒ ïîáîëåå áóäåò, ÷åì ó êàêîãî-òî òàì ïàðøèâîãî ãåëÿ.

Íó à åñëè ñåðüåçíî, òî Âû êîãäà ïûòàåòåñü öèòèðîâàòü èñëëåäîâàíèÿ, êîòîðûå ïî âàøåìó ìíåíèþ æàæäóò óâèäåñòü ñòîðîííèêè äîêàçàòåëüíîé ìåäèöèíû âñå æå èìåëè áû ââèäó, ÷òî ïðîñòî êðè÷àòü õàëâà (A multicentric, prospective, randomized, open study) äëÿ ñëàäîñòè ìàëî. ×òîáû óáåäèòüñÿ â äîñòîâåðíîñòè èññëåäîâàíèÿ, íàäî áû çíàòü åãî õàðàêòåðèñòèêè, â ò.÷. â öèôðàõ (ñì. ïîñò ä-ðà Ãèëÿðîâà). ß çàìåòèë, ÷òî â ïóáëèêàöèÿõ àëüòåðíàòèâøèêîâ ÷àñòî çâó÷àò òîëüêî âûøåóêàçàííûå "âîëøåáíûå" ñëîâà, à âñå îñòàëüíîå ïûòàþòñÿ êàê òî âñå áîëüøå ñêðûòü.
  #79  
Ñòàðûé 15.03.2003, 00:56
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
Îé, Àëåêñåé Âèêòîðîâè÷!
À ÿ óæ íàäåÿëñÿ, ÷òî Âû âñåðüåç ïîääåðæàëè ìîå ïðåäëîæåíèå áîëüøå íà ôîðóìå íå êîíòàêòèðîâàòü. Íó êàêèå åù¸ ïðèçíàíèé Âû îò ìåíÿ õîòèòå? ×òî ïî ìíå òþðüìà ïëà÷åò, òàê ÿ óæå â ýòîì äâàæäû ñ Âàìè ñîãëàøàëñÿ. ×òî Âû Âåëè÷àéøèé äîêòîð, è, âîîáùå, ñóäÿ ïî ïîñòàì, ãäå Âû àâòîðèòåòíåéøå îáñóæäàåòå ëþáûå âîïðîñû ìèðîçäàíèÿ – óìèùå ãîñóäàðñòâåííîãî ìàñøòàáà? Ïîæàëóéñòà.
Die Aufmerksamkeit, die Aufmerksamkeit! Attention, attention! L'attention, l'attention! Âíèìàíèå, âíèìàíèå! Ãðàæäàíå! Àëåêñåé Âèêòîðîâè÷, åù¸ áîëåå Âåëèêèé, ÷åì äàæå ñàì ñåáÿ îöåíèâàåò (õîòÿ óæ êóäà âûøå).

P.S. Íà ñ÷åò ÝÑÑÀÂÅÍ ÃÅËÜ – ýòî íå ÿ, ýòî èç èíñòðóêöèè.
Âîò åù¸ îäíà.
Âèäàëü >> Ôàðìàêîëîãè÷åñêèé ñïðàâî÷íèê >> ÊÀÐÄÈÎËÎÃÈß. ÀÍÃÈÎËÎÃÈß
ÝÑÑÀÂÅÍ (ESSAVEN)
ÝÑÑÀÂÅÍ ÃÅËÜ
RHONE-POULENC RORER

Ñîñòàâ è ôîðìà âûïóñêà:
Ãåëü: 40 èëè 100 ã â òóáàõ.
10 ã ýñöèí 100 ìã ãåïàðèíà íàòðèåâàÿ ñîëü 1000 ÌÅ «ýññåíöèàëüíûå» ôîñôîëèïèäû 100 ìã. «Ýññåíöèàëüíûå» ôîñôîëèïèäû — ñóáñòàíöèÿ EÐL (àêòèâíîå íà÷àëî: äèãëèöåðèäíûå ýôèðû õîëèíîôîñôîðíîé êèñëîòû ïðèðîäíîãî ïðîèñõîæäåíèÿ ñ ïðåîáëàäàíèåì ïîëèíåíàñûùåííûõ æèðíûõ êèñëîò, â îñíîâíîì ëèíîëåâîé — îêîëî 70%, ëèíîëåíîâîé è îëåèíîâîé êèñëîò).
Ôàðìàêîëîãè÷åñêîå äåéñòâèå:
Ýññàâåí ãåëü — ýôôåêòèâíîå âåíîòåðàïåâòè÷åñêîå ñðåäñòâî, äåéñòâèå êîòîðîãî îáóñëîâëåíî ýôôåêòàìè âõîäÿùèõ â åãî ñîñòàâ êîìïîíåíòîâ.
Ýñöèí óêðåïëÿåò êàïèëëÿðû; òîíèçèðóåò âåíû; îáëàäàåò àíòèýêññóäàòèâíûì (àíòèýäåìàòîçíûì) ýôôåêòîì; óëó÷øàåò ðåîëîãè÷åñêèå ñâîéñòâà êðîâè.
Ãåïàðèí îêàçûâàåò ïðîòèâîâîñïàëèòåëüíîå äåéñòâèå, ñïîñîáñòâóåò ýíäîãåííîìó ôèáðèíîëèçó, óëó÷øàåò ìèêðîöèðêóëÿöèþ.
«Ýññåíöèàëüíûå» ôîñôîëèïèäû (èëè ñóáñòàíöèÿ EPL) óëó÷øàþò ðåîëîãè÷åñêèå ñâîéñòâà êðîâè è ìèêðîöèðêóëÿöèþ.
Ýññàâåí ãåëü îáëàäàåò îõëàæäàþùèì äåéñòâèåì, ÷òî â äîáàâëåíèå ê ïðîòèâîâîñïàëèòåëüíûì ñâîéñòâàì îáóñëàâëèâàåò áîëåóòîëÿþùèé ýôôåêò.
Ïîêàçàíèÿ:
— âàðèêîçíîå ðàñøèðåíèå âåí;
— áîëåçíåííàÿ óñòàëîñòü íîã;
— íî÷íûå ñóäîðîãè èêðîíîæíûõ ìûøö;
— ôëåáèòû ïîâåðõíîñòíûõ âåí;
— êðîâîïîäòåêè è îòåêè âñëåäñòâèå ðàñòÿæåíèé è óøèáîâ;
— ñïîðòèâíûå òðàâìû.
Ðåæèì äîçèðîâàíèÿ:
Ýññàâåí ãåëü íàíîñÿò òîíêèì ðîâíûì ñëîåì íà îòå÷íûå è áîëåçíåííûå ó÷àñòêè òåëà 2-3 ðàçà/ñóò.
Âòèðàíèå ãåëÿ íå ÿâëÿåòñÿ íåîáõîäèìûì è â ñëó÷àå âîñïàëèòåëüíûõ ïðîöåññîâ äàæå íåæåëàòåëüíî.

Ïîáî÷íîå äåéñòâèå:
Êðàéíå ðåäêî àëëåðãè÷åñêèå èëè ïñåâäîàëëåðãè÷åñêèå ðåàêöèè (vasculitus allergica).
Ïðîòèâîïîêàçàíèÿ:
Ïîâûøåííàÿ ÷óâñòâèòåëüíîñòü ê êàêîìó-ëèáî èç êîìïîíåíòîâ, âõîäÿùèõ â ñîñòàâ ïðåïàðàòà.

Òóò ÿ áûëî çàáåñïîêîèëñÿ íåóæåëè Essaven gel ìèíîâàëè randomized, placebo-controlled, double-blind study. Ïîëåç âûÿñíÿòü - êàìåíü ñ äóøè óïàë: õîòü ñ ýòèì âñå â ïîðÿäêå.
  #80  
Ñòàðûé 15.03.2003, 01:17
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
Ìèõàèë Þðüåâè÷!
À âîò ñ Âàìè ìíå äåéñòâèòåëüíî îáèäíî, ÷òî òàê è íå óäàëîñü õîòü íåìíîãî ðàçâåÿòü Âàø ñêåïñèñ.
  #81  
Ñòàðûé 15.03.2003, 08:51
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Smile Âû çàáàâíûé ìàëûé, Âëàäèìèð ßêîâëåâè÷!

Âëàäèìèð ßêîâëåâè÷!
Íó çà÷åì êðèâëÿòüñÿ òî? Íó íåóæåëè Âû íå ïîíèìàåòå, ÷òî ñïðàâî÷íèê Âèäàëü ýòî íå ïåðå÷åíü ñòàíäàðòîâ ëå÷åíèÿ ê.ë. çàáîëåâàíèé, óòâåðæäåííûõ êàêîé-ëèáî ïðîôèëüíîé ñîãëàñèòåëüíîé êîìèññèåé? È ïî÷åìó âàøè èòàëüÿíñêèå êîëëåãè âûáðàëè èìåííî ýòîò ãåëü? Ìîæåò ýòî êàêîé íèáóäü òàì over the counter medication? ×åãî òîãäà íå ïðîâåñòè èññëåäîâàíèÿ â ñðàâíåíèè ñ êåðîñèíîì èëè ãóòàëèíîì? È åñëè Âû íàøëè, ÷òî ýòî äåéñòâèòåëüíî ñòàíäàðòíîå ñðåäñòâî, êîòîðîå ðåøàåò êàêèå òî ïðîáëåìû - ïðèâåäèòå ññûëêè. È îïÿòü æå Âû ñàìè âñå âðåìÿ ãîâîðèòå, ÷òî ñëîâî ðàíäîìèçàöèÿ èñïîëüçóåòñÿ êàê çàêëèíàíèå. Òàê âîò öèòèðîâàííûé âàìè òåçèñ ñîäåðæèò òîëüêî çàêëèíàíèÿ. Îí íå ïîçâîëÿåò îöåíèòü êà÷åñòâî è óðîâåíü äîêàçàòåëüíîñòè ïðîäåëàííîé ðàáîòû.

×òî äî ìèðîâûõ ïðîáëåì. èõ èìååò ïðàâî îáñóæäàòü ëþáîé ðåáåíîê è âîîáùå êòî óãîäíî. Ïî÷åìó Âû îòíèìàåòå ó ìåíÿ ïðàâî âûñêàçûâàòü ñîáñòâåííîå ìíåíèå? Èëè ñîâîê ïî âàì òàê ïðîåõàëñÿ, ÷òî Âû äî ñèõ ïîð ïîëàãàåòå, ÷òî ïðàâî âûñêàçûâàòüñÿ ïî âîïðîñàì "âñåëåíñêîãî" ìàñòøòàáà èìåþò òîëüêî ëèöà íå íèæå ÷ëåíîâ ãîðêîìà ÊÏÑÑ?
  #82  
Ñòàðûé 15.03.2003, 12:04
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
All right, Àëåêñåé Âèêòîðîâè÷!
È «ñîâîê» íà ìíå òàê íàåçäèëñÿ, ÷òî â êàìáàëó ïðåâðàòèë (ïîýòîìó íà øèðèíå êàìåðû, êîòîðóþ Âû ìíå âñå âðåìÿ ïðîðî÷èòå, ìîæíî áóäåò ñýêîíîìèòü). È Âû íåñðàâíèìî âûøå ëþáîãî «÷ëåíà ãîðêîìà ÊÏÑÑ». Ïîýòîìó íå òîëüêî ìîæåòå, à ïðîñòî îáÿçàíû ïðîñâåùàòü ïðèñóòñòâóþùèõ ðåöåïòàìè ðåøåíèÿ ëþáûõ ìèðîâûõ ïðîáëåì. Íî òîëüêî áåç ìåíÿ.
Ïðè÷èíû ïîâòîðÿòü íå áóäó. Íå ãîâîðÿ óæ î òîì, ÷òî íè íà éîòó íå âåðþ â âîçìîæíîñòü áåñïðèñòðàñòíîñòè, åñëè èíôîðìàöèÿ áóäåò ïðîòèâîðå÷èòü Âàøåìó óñòîÿâøåìóñÿ ìèðîâîççðåíèþ, ñêîëüêî áû Âû íå óâåðÿëè â ïðîòèâíîì.
  #83  
Ñòàðûé 15.03.2003, 12:31
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
Äà, íà âñÿêèé ñëó÷àé, ïî ïîâîäó «êàêîãî-òî òàì ïàðøèâîãî ãåëÿ».
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]!
  #84  
Ñòàðûé 16.03.2003, 15:38
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
Åù¸ äîïîëíèòåëüíàÿ èíôîðìàöèÿ ñâÿçàííàÿ ñ îçîíîòåðàïèè.
Õî÷ó ñðàçó îòìåòèòü, ÷òî íîâûå, äîïîëíèòåëüíûå äàííûå ïî ÎÒ, ïðèâîæó îòíþäü íå äëÿ àãèòàöèè ïðèñóòñòâóþùèõ âðà÷åé. Êàê ïðàâèëî, ó âðà÷åé ïîÿâëÿåòñÿ èíòåðåñ ê ýòîé òåðàïèè òîëüêî ïîñëå îáùåíèÿ ñ êîëëåãàìè, å¸ ïðàêòèêóþùèìè.
Íî íà ôîðóìå, íå ðàç ðàçäàâàëèñü áóðíûå ïðîäîëæèòåëüíûå àïëîäèñìåíòû, ïîñëå «íàåçäîâ» íà ìåíÿ òèïà: «òàêóþ øàðëàòàíñêóþ ( êàê âàðèàíò, ôàøèñòñêóþ) òåðàïèþ ìîãóò âòþðèâàòü òîëüêî â òàêîé àôðèêàíñêîé ñòðàíå, êàê Ðîññèÿ».
«Ïî Âàì ã-í Çàéöåâ äàâíî òþðüìà ïëà÷åò, è ò.ï.». Âîò ÿ è ñòàðàþñü, ÷òîáû ìîè îïïîíåíòû ïðèêèíóëè: íåëüçÿ ëè äëÿ ìåíÿ óñëîâíûì ñðîêîì îãðàíè÷èòñÿ?


Ñíà÷àëà. Åù¸ îäíî ïîäòâåðæäåíèå, ÷òî äàæå â ÑØÀ îçîíîòåðàïèþ èñïîëüçóþò â êëèíèêàõ äëÿ ëå÷åíèÿ ðàçëè÷íûõ çàáîëåâàíèé. È ÍÅ ÑÀÆÀÞÒ!

OZ-PO-050: THE USE OF OZONE IN COLONIC THERAPY.
Dr. Dirk Yow.
Tahoma Clinic, Kent, Washington, USA.
This paper reviews the outcome of a combination of ozone therapy with colonics administered (herbal enemas) through the methods passed on in the naturopathic tradition in the USA, in the last three years. The relationship of ozone and its oxidative properties along side an ability to enhance the colonyc hydrotherapy responses in a variety of factors related to various symptoms and ailments will be discuss. 250 patients (men and women with an age range between 15 and 85) were received into therapy in the Colon Therapy Department by self referral, after an evaluation of a health questionnaire performed by the medical director, or by referral from a physician. Of the patients treated the major indications were: gastro-intestinal complaints, cutaneous conditions, malaise and chronic fatigue, arthritic conditions and others. It is postulated that the methods of achieving benefit accrue through: 1.Drainage and treatment of infected tissues, 2. Breaking the formation of vicious cycles in auto-intoxification, 3. Building up immunity against infection, 4.Treating specific infectious organisms, 5. Defining secondary foci and primary foci. The clinical benefit ratio for this form of therapy, as an adjunct to other modalities, is favorable.

Òåïåðü ê âîïðîñó, êîòîðûé ìíå óæå çàäàâàëñÿ. ÎÒ â îíêîëîãèè. Õîòÿ, êàê ÿ óæå ñîîáùàë, èññëåäîâàíèé ÎÒ â ýòîé îáëàñòè ïîêà íåäîñòàòî÷íî è îíè ðàçðîçíåíû äëÿ êàêèõ-ëèáî îêîí÷àòåëüíûõ âûâîäîâ.

OZ-PO-039: TUMOR pO2 MODIFICATION BY OZONETHERAPY.
B. Clavo (a), M. Lloret (a), L. López (a), G. Suárez (a), M. Santana (a), J.L. Pérez (b), V. Rodríguez (c), D. Macías (b), M.A. Hernández (a), R. Martín-Oliva (b), G. Rovira (d) and M Günderoth (e).
(a) Pino Hospital: Radiation Oncology-Research Unit, Las Palmas, (b) Pino Hospital: Medical Physics Unit., Las Palmas, (c) La Paterna Center, Las Palmas, (d) Quiron Clinic, Barcelona, Spain, (e) Helzel Medical Systems,Germany.
Hypoxic tumor cells are 2.5 - 3 times more resistant to radiotherapy, with higher metastatic potential than normoxic cells. Tumor hypoxia is an independent prognostic factor in head and neck and uterine cervix tumors. As has been demonstrated by the meta-analysis of Overgaard and the multicenter clinical trials, hypoxia modification prior to or during the course of radiotherapy can increase the effectiveness of treatment and improve prognosis. Ozonetherapy (O3T) has been used to treat ischemic disorders. This study evaluated the effect of O3T on tumor pO2 in humans. We study 16 patients with advanced or relapsed cancer: Male:Female 13 : 3, between 50 – 91 years old. O3T was carried out by autohemotransfusion 3 alternating days over one week. Tumour pO2 was measured by a polarographic probe system, four times. There were 150-200 determinations every time. During O3T there was significant increase (Friedman test: p = 0.013) in tumor oxygenation and decrease of hypoxic fractions, with prolonged effect. There was inverse and significant correlation between individual "Increase Factor" and "initial pO2 value": higher increase oxygenation in those initially worse oxygenated tumors (Spearman rho = - 0.885, p < 0.001. These findings support that ozone therapy could be a useful adjuvant in treatment of hypoxic tumors.
  #85  
Ñòàðûé 16.03.2003, 20:27
Gallen Gallen âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 14.07.2002
Ãîðîä: UA
Ñîîáùåíèé: 6,085
Ñêàçàë(à) ñïàñèáî: 1
Ïîáëàãîäàðèëè 568 ðàç(à) çà 534 ñîîáùåíèé
Gallen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGallen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGallen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGallen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGallen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGallen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGallen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGallen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGallen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGallen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGallen ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Çäðàâñòâóéòå. Ýòî îïÿòü ÿ
Ïðîñòèòå, ÷òî íå â òåìó, íî...
Íåäàâíî ÿ ïîîáùàëñÿ ñ ãîìåîïàòîì, òàê ñêàçàòü, â î÷íîé ñòàâêå. ظë "ïîäãîòîâëåííûì", íà÷èòàííûì, âî âñåîðóæèè. À îí ìåíÿ ïðîñòî ðàçîðóæèë - ñêàçàë, ÷òî íå îáèæàåòñÿ óæå äàâíî íà âûïàäû êëàññè÷åñêèõ ìåäèêîâ, ò.ê. íå ñîìíåâàåòñÿ â ýôôåêòèâíîñòè, è íèêîìó íè÷åãî íå ñîáèðàåòñÿ äîêàçûâàòü.
Ìîë, Âû ñ÷èòàåòå íåýôôåêòèâíî - ýòî Âàøè ïðîáëåìû. Õîòèòå èçó÷àòü, ïðîâåðÿòü - âàëÿéòå. È òàê äàëåå â òîì æå äóõå.
È ÿ äëÿ ñåáÿ ïîíÿë - ÷¸ íàä óáîãèìè ñìåÿòüñÿ (èëè ñ íèìè ñïîðèòü) - êàæäîìó ñâî¸. Îáèäíî òîëüêî, êîãäà óõóäøåíèå, êîòîðîãî ìîæíî áûëî èçáåæàòü...
  #86  
Ñòàðûé 16.03.2003, 22:19
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Îçîíîòåðàïèþ èñïîëüçóþò, ãëàâíûì îáðàçîì, íå ãîìåîïàòû, à ÷òî íè íà åñòü êëàññè÷åñêèå ìåäèêè, ïðè÷åì äîâîëüíî êðóïíûõ è èçâåñòíûõ ìåäèöèíñêèõ öåíòðîâ.
Ñëîâ íåò! Ïîëíûé ôèíèø! Ýòî êàê â òîì àíåêäîòå ïðî ïîðó÷èêà Ðæåâñêîãî, "íè ñëîâà î ...
Íó à åñëè ñåðüåçíî, ÿ áû òàêèõ "êëàññè÷åñêèõ" ìåäèêîâ, êîòîðûå â "êðóïíûõ è èçâåñòíûõ" ë.ó. áåç èíôîðìèðîâàííîãî ñîãëàñèÿ áîëüíûõ ïûòàëèñü áû "ëå÷èòü" ìåòîäîì â ñòàíäàðòû ëå÷åíèÿ ÍÈ ÎÄÍÎÃÎ ÇÀÁÎËÅÂÀÍÈß Â ÌÈÐÅ íå âõîäÿùèì, ïðîñòî ëèøàë áû äèïëîìà. Íó à ïðåæäå ÷åì ññûëàòüñÿ íà àìåðèêàíöåâ (ïðèâåäåííûé òåçèñ êàê âñåãäà íå ïðîèçâîäèò íèêàêîãî íàó÷íî-äîêàçàòåëüíîãî âïå÷àòëåíèÿ, îòêóäà Âû èõ äîñòàåòå òîëüêî? Íåáîñü îïÿòü ñ êàêèõ íèáóäü ðåêëàìíûõ ñàéòîâ?) Âû áû õîòü ïîèíåòåðñîâàëèñü: ÷òî çà êëèíèêà, ãäå èñïîëüçîâàëñÿ ÎÒ (åå ñòàòóñ è, ãëàâíîå, ñòàòóñ åå professional liability), êàêîâà áûëà þðèäè÷åñêàÿ îñíîâà "ëå÷åíèÿ" ýòèõ self referred patients òðàâàìè-ìóðàâàìè â êëèçìàõ è ïð. íàòóðîïàòèåé íå îäîáðåííîé FDA? Âîò êîãäà Âû ýòî óçíàåòå è ÷åñòíî îïóáëèêóåòå (â ÷åì îîîî÷åíü ñèëüíî ñîìíåâàþñü), Âàø ïðèìåð ñòàíåò õîòü íåìíîãî óáåäèòåëüíûì. Íó à ïîêà... ß Âàì â ëþáîì óãîëêå Àìåðèêè ìîãó ðàçûñêàòü íå îäèí äåñÿòîê ðàçíîãî ðîäà òàê ñêàçàòü out of medicine íàòóðîïàòîâ. Íó ïðàêòèêóþò îíè ñåáå âñÿêîãî ðîäà ýêçîòèêó, íî ìåäèöèíîé ýòî â ÑØÀ íèêòî íå ñ÷èòàåò.

Äà, åñëè Âàø ãëàâíûé îïïîíåíò ÿ, òî êîãäà ýòî ÿ Âàñ ïðèíóäèòåëüíûì ëå÷åíèåì òî ñòðàùàë, ÷å òî íå ïðèïîìíþ. Âû óæ òàê ýòî àâòîìàòè÷åñêè ñâîè àññîöèàöèè â ñêàçàííîå äðóãèìè íå ïåðåâîäèòå ïîæàëóéñòà.

Õîòåëîñü áû åùå ðàç óñëûøàòü ìíåíèå êîëëåã ïî ïîâîäó êà÷å÷òâà ïðèâåäåííûõ Âëàäèìèðîì ßêîâëåâè÷åì öèòàò.
  #87  
Ñòàðûé 16.03.2003, 22:29
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ñíà÷àëà. Åù¸ îäíî ïîäòâåðæäåíèå, ÷òî äàæå â ÑØÀ îçîíîòåðàïèþ èñïîëüçóþò â êëèíèêàõ äëÿ ëå÷åíèÿ ðàçëè÷íûõ çàáîëåâàíèé. È ÍÅ ÑÀÆÀÞÒ!
Íó ÷òî æ, îïÿòü Âû òóò ïóáëèêó çàïóòàòü ïîïûòàëèñü. Ýòà ñàìàÿ Tahoma Clinic åñòü íå ÷òî èíîå êàê ÷àñòíàÿ êëèíèêà àëüòåðíàòèâíîé ìåäèöèíû, êîòîðàÿ íè ìàëåéøåãî îòíîøåíèÿ ê íàó÷íîé ìåäèöèíå íå èìååò. Òîëüêî ÷òî âûÿñíèë ÷åðåç Yahoo! Ïðèìåð, Âëàäèìèð ßêîâëåâè÷, êàê âñåãäà íåóäà÷åí èáî íèêàêîãî îòíîøåíèÿ ê àìåðèêàíñêîé ìåäèöèíå íå èìååò.
  #88  
Ñòàðûé 16.03.2003, 23:07
Àâàòàð äëÿ Melnichenko
Melnichenko Melnichenko âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 26.07.2001
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 117,195
Ñêàçàë(à) ñïàñèáî: 26
Ïîáëàãîäàðèëè 33,590 ðàç(à) çà 32,664 ñîîáùåíèé
Melnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Òåêñò , ïîñâÿùåííûé ëîêàëüíîé ëèïîäèñòðîôèè , íàñòîëüêî íåâíÿòåí , óâàæàåìûé Âëàäèìèð ßêîâëåâè÷ , ÷òî ÿ ïîñòåñòíÿëàñü áû åãî öèòèðîâàòü . Âû ñàìè -òî ïðåäñòàâëÿåòå ñåáå , î êàêèõ âîîáùå ëèïîäèñòðîôèÿõ èäåò ðå÷ü ? È ïîäîçðåâàåòå ëè Âû , ÷òî ñïðàâî÷íèê Âèäàëÿ - íå ìîëèòâåííèê , è ìíîæåñòâî óêàçûâàåìûõ òàì ïðåïàðàòîâ íèêîãäà íå èçó÷àëèñü ñ èñïîëüçîâàíèé ñîâðåìåííîãî íàó÷íîãî àïïàðàòà . Îíè ñóùåñòâóþò ñ íåçàïàìÿòíûõ âðåìåí ( à èçúÿòü ïðåïàðàò èç íîìåíêëàòóðû îõ êàê ñëîæíî ) .
__________________
Ã.À. Ìåëüíè÷åíêî
  #89  
Ñòàðûé 16.03.2003, 23:37
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
Íó à åñëè ñåðüåçíî, ÿ áû òàêèõ "êëàññè÷åñêèõ" ìåäèêîâ

Øóìèì áðàò, øóìèì.
Àëåêñåé Âèêòîðîâè÷!
Äà åñëè Âàì äàòü âîëþ – ñòðàøíî ïîäóìàòü, æóòü. Õîðîøî, ïóñòü â ÑØÀ (â îòëè÷èå îò Åâðîïû) êëèíèêè àëüòåðíàòèâíîé ìåäèöèíû. È íå îäíà, è äàæå íå äåñÿòü. Òàê âåäü íå ñàæàþò! À ìíå êòî òþðüìîé ìíå ãðîçèë?
Ê ñëîâó, Âû òóò êàê-òî òðåáîâàëè: ïðèâåäèòå õîòü îäíó óíèâåðñèòåòñêóþ êëèíèêó!
Òîëüêî íà ôîðóìå «ÎÇÎÍÎÒÅÐÀÏÈß ÏÐÈ ÑÀÕÀÐÍÎÌ ÄÈÀÁÅÒÅ» ÿ çà ïîñëåäíåå âðåìÿ ïðèâåë ñ äåñÿòîê. Áóäåì èõ çàêðûâàòü?
È ÷òî-òî ïî ïîâîäó «êàêîãî-òî òàì ïàðøèâîãî ãåëÿ», Âû ïîøóìåëè è ïðèóìîëêëè. Ñëþíà êîí÷èëàñü?

P.S. È, ïîæàëóéñòà, îñòàâüòå çà ñëåïîé, óñðåäíåííîé, ñòàòèñòè÷åñêîé ìåäèöèíîé ýïèòåò «äîêàçàòåëüíàÿ», «íàó÷íàÿ» óæ î÷åíü óõî ðåæåò.
  #90  
Ñòàðûé 16.03.2003, 23:46
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
Óâàæàåìàÿ Ãàëèíà Àôàíàñüåâíà!
Êàê Âû ìîãëè áû çàìåòèòü îñíîâíîé òåêñò ñòàòüè çàíèìàåò 16 ñòðàíèö, íî îí íà èòàëüÿíñêîì è ó ìåíÿ åãî íåò. ß ïðèâåë âûâîäû.
À ïî ïîâîäó ãåëÿ, êîòîðûé íèêîãäà íå èçó÷àëèñü ñ èñïîëüçîâàíèåì ñîâðåìåííîãî íàó÷íîãî àïïàðàòà , åù¸ ðàç ïðèâîæó ññûëêó ïî êëèíè÷åñêèì èñïûòàíèÿì òîëüêî çà ïîñëåäíèå ãîäû, â ðàçíûõ ñòðàíàõ.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]!
 


Îïöèè òåìû Ïîèñê â ýòîé òåìå
Ïîèñê â ýòîé òåìå:

Ðàñøèðåííûé ïîèñê
Îïöèè ïðîñìîòðà

Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 11:10.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.